Montara Therapeutics key facts
as of Oct 2026- Operator of a biopharmaceutical company intended to enhance the safety and efficacy of treatments for neurological diseases.
- Montara Therapeutics is valued at approximately $55.0M as of Oct 2026, set at its seed round, Feb 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $28.0M across 2 recorded rounds; the latest was Early Stage VC ($20.0M) in Feb 2025.
- Notable investors include Dolby Family Ventures, SV Health Investors, Bayshore Global Management, BEVC (Berkeley), KdT Ventures — 8 tracked in total.
- Montara Therapeutics has filed 2 Form Ds with the SEC since 2024, most recently Mar 2025 ($20.0M sold to 9 investors).
- Status: Privately Held (backing).
Valued at $55.0M at its seed round, Feb 2025. Nothing has traded since.
- ·Watch Montara Therapeutics: the Monday email on marks, rounds and moves
Montara Therapeutics funding rounds
2 roundsMontara Therapeutics valuation
Montara Therapeutics was valued at $55 million at its seed round in Feb 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Montara Therapeutics raised?
Montara Therapeutics has raised $28 million across 2 recorded rounds since 2024. The largest was an $8 million early-stage round in Jan 2024; the most recent was a $20 million early-stage round in Feb 2025.
Montara Therapeutics has filed 2 Form Ds with the SEC since 2024, most recently in Mar 2025 ($20 million sold to 9 investors).
Montara Therapeutics investors
8 investors are on record for Montara Therapeutics, including Dolby Family Ventures, SV Health Investors, Bayshore Global Management and BEVC (Berkeley). The early-stage round in Feb 2025 drew 9 investors.
About Montara Therapeutics
Operator of a biopharmaceutical company intended to enhance the safety and efficacy of treatments for neurological diseases. The company specializes in brain-specific pharmacology by leveraging human genetics and machine learning to identify and validate drug targets, enabling medical professionals to develop therapies for previously undruggable targets and improving treatment outcomes for patients with neurological conditions.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2023
- Employees
- 21
- Website
- montaratx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.